$FATE
Fate Therapeutics Inc

2021 Q1 Form 10-Q Financial Statement

#000156459021024037 Filed on May 05, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $11.14M $2.515M
YoY Change 343.02% -4.45%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $12.50M $7.730M
YoY Change 61.71% 44.49%
% of Gross Profit
Research & Development $44.85M $29.28M
YoY Change 53.19% 65.15%
% of Gross Profit
Depreciation & Amortization $959.0K $705.0K
YoY Change 36.03% 60.23%
% of Gross Profit
Operating Expenses $57.35M $37.01M
YoY Change 54.98% 60.36%
Operating Profit -$46.21M -$34.49M
YoY Change 33.97% 68.7%
Interest Expense $1.120M $970.0K
YoY Change 15.46% 139.51%
% of Operating Profit
Other Income/Expense, Net $1.121M $972.0K
YoY Change 15.33% 41.69%
Pretax Income -$45.09M -$33.52M
YoY Change 34.52% 69.64%
Income Tax
% Of Pretax Income
Net Earnings -$45.09M -$33.52M
YoY Change 34.51% 69.64%
Net Earnings / Revenue -404.68% -1332.8%
Basic Earnings Per Share
Diluted Earnings Per Share -$482.6K -$441.7K
COMMON SHARES
Basic Shares Outstanding 93.78M 75.93M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $790.1M $203.3M
YoY Change 288.64% 11.09%
Cash & Equivalents $106.4M $83.37M
Short-Term Investments $683.7M $119.9M
Other Short-Term Assets $7.200M $5.000M
YoY Change 44.0% 72.41%
Inventory
Prepaid Expenses
Receivables $6.900M
Other Receivables $0.00
Total Short-Term Assets $804.3M $208.2M
YoY Change 286.22% 11.7%
LONG-TERM ASSETS
Property, Plant & Equipment $115.2M $11.90M
YoY Change 868.39% 41.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $98.30M $16.10M
YoY Change 510.56%
Other Assets $15.20M $9.000K
YoY Change 168788.89% -95.5%
Total Long-Term Assets $241.7M $113.6M
YoY Change 112.69% 229.68%
TOTAL ASSETS
Total Short-Term Assets $804.3M $208.2M
Total Long-Term Assets $241.7M $113.6M
Total Assets $1.046B $321.9M
YoY Change 224.96% 45.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.000M $5.173M
YoY Change 73.98% -4.2%
Accrued Expenses $20.93M $11.77M
YoY Change 77.83% 5.09%
Deferred Revenue $2.923M
YoY Change -55.55%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $94.60M $24.92M
YoY Change 279.55% -14.47%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $161.3M $77.70M
YoY Change 107.59% 122.64%
Total Long-Term Liabilities $161.3M $77.70M
YoY Change 107.59% 609.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $94.60M $24.92M
Total Long-Term Liabilities $161.3M $77.70M
Total Liabilities $255.9M $102.7M
YoY Change 149.17% 156.12%
SHAREHOLDERS EQUITY
Retained Earnings -$417.1M
YoY Change 36.67%
Common Stock $76.00K
YoY Change 16.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $790.1M $219.2M
YoY Change
Total Liabilities & Shareholders Equity $1.046B $321.9M
YoY Change 224.96% 45.74%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$45.09M -$33.52M
YoY Change 34.51% 69.64%
Depreciation, Depletion And Amortization $959.0K $705.0K
YoY Change 36.03% 60.23%
Cash From Operating Activities -$27.10M -$26.67M
YoY Change 1.59% 52.48%
INVESTING ACTIVITIES
Capital Expenditures $3.981M $1.070M
YoY Change 272.06% -38.72%
Acquisitions
YoY Change
Other Investing Activities -$467.9M $24.84M
YoY Change -1983.7% 136.57%
Cash From Investing Activities -$471.9M $23.77M
YoY Change -2084.89% 171.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 438.1M 1.451M
YoY Change 30089.52% 15.34%
NET CHANGE
Cash From Operating Activities -27.10M -26.67M
Cash From Investing Activities -471.9M 23.77M
Cash From Financing Activities 438.1M 1.451M
Net Change In Cash -60.93M -1.448M
YoY Change 4108.15% -80.64%
FREE CASH FLOW
Cash From Operating Activities -$27.10M -$26.67M
Capital Expenditures $3.981M $1.070M
Free Cash Flow -$31.08M -$27.74M
YoY Change 12.02% 44.2%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5892000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
46021000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32308000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
67084000
CY2021Q1 fate Cirm Award Liability Noncurrent
CIRMAwardLiabilityNoncurrent
800000
CY2020Q4 fate Cirm Award Liability Noncurrent
CIRMAwardLiabilityNoncurrent
800000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5515000
CY2020Q4 fate Short Term Investments And Related Maturity Receivables
ShortTermInvestmentsAndRelatedMaturityReceivables
315569000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
494323000
CY2021Q1 us-gaap Long Term Investments
LongTermInvestments
98284000
CY2021Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
15227000
CY2020Q4 us-gaap Contract With Customer Asset Net Noncurrent
ContractWithCustomerAssetNetNoncurrent
13506000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9000
CY2020Q4 us-gaap Assets
Assets
622457000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6283000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15564000
CY2020Q4 fate Cirm Award Liability Current
CIRMAwardLiabilityCurrent
3200000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
21144000
CY2021Q1 fate Stock Price Appreciation Milestones Liabilities Current
StockPriceAppreciationMilestonesLiabilitiesCurrent
36003000
CY2020Q4 fate Stock Price Appreciation Milestones Liabilities Current
StockPriceAppreciationMilestonesLiabilitiesCurrent
36018000
CY2021Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
43025000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
93943000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3355000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
106512000
CY2021Q1 fate Stock Price Appreciation Milestones Liabilities Non Current
StockPriceAppreciationMilestonesLiabilitiesNonCurrent
10955000
CY2020Q4 fate Stock Price Appreciation Milestones Liabilities Non Current
StockPriceAppreciationMilestonesLiabilitiesNonCurrent
11684000
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
93888679
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
93888679
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
87722237
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
87722237
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-46210000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
377000
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
972000
CY2021Q1 fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
-744000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1121000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
972000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-33520000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-45419000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
75886964
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-33520000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
705000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6913000
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1140000
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-271000
CY2021Q1 us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
623000
CY2020Q1 us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
168000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3107000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-515000
CY2021Q1 fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
-744000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1430000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1301000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-636000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6944000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3316000
CY2021Q1 fate Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
1933000
CY2020Q1 fate Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
1985000
CY2021Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
529907000
CY2021Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
62000000
CY2020Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
24844000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-471888000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5605000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1011000
CY2021Q1 fate Proceeds From Public Offering Of Common Stock And Issuance Of Pre Funded Warrants Net Of Issuance Costs
ProceedsFromPublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrantsNetOfIssuanceCosts
432445000
CY2020Q1 fate Proceeds From Cirm Award
ProceedsFromCIRMAward
440000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
438050000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1451000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-60934000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1448000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
182574000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
100041000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
121640000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
98593000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2624000
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
343000
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1444000
CY2020Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
47808000
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
3548000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
98593000
CY2021Q1 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
15200000
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s unaudited condensed consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The preparation of the Company’s unaudited condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s unaudited condensed consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company’s unaudited condensed consolidated financial statements relate to its stock price appreciation milestone obligations, contracts containing leases, accrued expenses, stock-based compensation, and the estimated total costs expected to be incurred under the Company’s collaboration agreements. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</p>
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
106413000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
83366000
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
15227000
CY2020Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
15227000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
121640000
CY2020Q1 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
15200000
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25900000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-45100000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25500000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-33500000
CY2021Q1 fate Period To Treat Award As Grant If Award Not Treated As Loan
PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan
P10Y
CY2021Q1 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2020 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2020 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2020Q1 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2020Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2021Q1 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2021Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2021Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2021Q1 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2020Q1 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2020Q4 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2021Q1 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2021Q1 us-gaap Share Price
SharePrice
82.45
CY2021Q1 us-gaap Share Price
SharePrice
82.45
CY2021Q1 us-gaap Variable Lease Cost
VariableLeaseCost
235000
CY2020Q1 us-gaap Variable Lease Cost
VariableLeaseCost
610000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
3769000
CY2021Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q1 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q1 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
8373000
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
4815000
CY2021Q1 fate Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
6814000
CY2020Q4 fate Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
5244000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5744000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5505000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20931000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15564000
CY2021Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
These leases have terms varying from one to approximately sixteen years, with renewal options of up to ten years
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P13Y2M12D
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.084
CY2021Q1 us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
3534000
CY2020Q1 us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
2938000
CY2020Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
600000
CY2021Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
10274000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
13217000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
12988000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
13378000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
13779000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
14193000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
116254000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
194083000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
83159000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
110924000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12976000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6913000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
384445000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5648000
CY2021Q1 fate Public Offering Of Common Stock And Issuance Of Pre Funded Warrants
PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants
432445000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-330000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-45089000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
790095000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
244756000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
979000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6913000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
120000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-33520000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
219248000

Files In Submission

Name View Source Status
0001564590-21-024037-index-headers.html Edgar Link pending
0001564590-21-024037-index.html Edgar Link pending
0001564590-21-024037.txt Edgar Link pending
0001564590-21-024037-xbrl.zip Edgar Link pending
fate-10q_20210331.htm Edgar Link pending
fate-10q_20210331_htm.xml Edgar Link completed
fate-20210331.xsd Edgar Link pending
fate-20210331_cal.xml Edgar Link unprocessable
fate-20210331_def.xml Edgar Link unprocessable
fate-20210331_lab.xml Edgar Link unprocessable
fate-20210331_pre.xml Edgar Link unprocessable
fate-ex311_7.htm Edgar Link pending
fate-ex312_8.htm Edgar Link pending
fate-ex321_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending